100 papers found
Refreshing results…
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data
Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma
The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output
Pathologic Characteristics of Pregnancy-Related Meningiomas
Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors
Regional Differences in Neuroinflammation-Associated Gene Expression in the Brain of Sporadic Creutzfeldt–Jakob Disease Patients
Expression of the stem cell marker CD133 in malignant meningioma
Distinct circular RNA expression profiles in pediatric ependymomas
Mitotic and Proliferative Indices in WHO Grade III Meningioma
Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis
TERT promoter mutations in primary and secondary WHO grade III meningioma
Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2
In vivo imaging of cell proliferation in meningioma using 3′-deoxy-3′-[18F]fluorothymidine PET/MRI
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis
Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma
Rare-21. Clinical Characteristics of Gliosarcoma and Outcome From Standardized Treatment Relative to Conventional Glioblastoma
Mngi-08. Pharmacokinetic Analysis of 68ga-Dotatoc in Meningiomas Using Pet/Ct for Assessment of Somatostatin Receptors and Correlation With Angiogenesis, Inflammation and Proliferation
Path-28. Angiotensinogen Promoter Methylation to Predict Bevacizumab Response in Recurrent Glioblastoma Patients
Missing publications? Read more about our data sources.